Drug reference

Ceftolozane with tazobactam

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 580, 581

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Complicated intra-abdominal infection ▶BY INTRAVENOUS INFUSION ▶Adult: 1/0.5 g every 8 hours for 4–14 days Complicated urinary tract infection | Acute pyelonephritis ▶BY INTRAVENOUS INFUSION ▶Adult: 1/0.5 g every 8 hours for 7 days Hospital-acquired pneumonia | Ventilator-associated pneumonia ▶BY INTRAVENOUS INFUSION ▶Adult: 2/1 g every 8 hours for 8–14 days DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y g where x and y are ceftolozane and tazobactam respectively.

PDF page 580

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions SMC No. 1146/16 The Scottish Medicines Consortium has advised (May 2016) that ceftolozane with tazobactam (Zerbaxa ®) is not recommended for use within NHS Scotland for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis as the clinical and economic case was not demonstrated.

PDF page 581

Safety

Interactions

→Appendix 1: cephalosporins

PDF page 580

Side Effects

▶Common or very common Antibiotic associated colitis. anxiety. constipation. electrolyte imbalance. hypotension . insomnia. thrombocytosis ▶Uncommon Anaemia. angina pectoris. arrhythmias. dyspnoea. gastrointestinal discomfort. gastrointestinal disorders. hyperglycaemia. increased risk of infection. ischaemic stroke. renal impairment. venous thrombosis

PDF page 580

Pregnancy

Manufacturer advises to use only if potential beneﬁt outweighs risk—toxicity in animal studies with tazobactam.

PDF page 580

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 580

Renal Impairment

Manufacturer advises monitor for changes in renal function. Dose adjustments ▶When used for Complicated intra-abdominal infection or Complicated urinary tract infection or Acute pyelonephritis Manufacturer advises reduce dose to 500/250 mg every 8 hours if creatinine clearance 30–50 mL/minute and 250/125 mg every 8 hours if creatinine clearance 15–29 mL/minute. ▶When used for Hospital-acquired pneumonia or Ventilator- associated pneumonia Manufacturer advises reduce dose to 1/0.5 g every 8 hours if creatinine clearance 30–50 mL/minute and 500/250 mg every 8 hours if creatinine clearance 15–29 mL/minute.

PDF page 580

Dose and formulations

Directions For Administration

For intravenous infusion (Zerbaxa ®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute initially each vial with 10 mL Water for Injections or Sodium chloride 0.9% to give a ﬁnal volume of 11.4 mL; dilute requisite dose in 100 mL of Glucose 5% or Sodium chloride 0.9%; give over 1 hour. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator at 2°C–8°C.

PDF pages 580, 581

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ELECTROLYTES: May contain Sodium ▶Zerbaxa (Merck Sharp & Dohme Ltd) A Tazobactam (as Tazobactam sodium) 500 mg, Ceftolozane (as Ceftolozane sulfate) 1 gram Zerbaxa 1g/0.5g powder for concentrate for solution for infusion vials | 10 vial P £670.30 (Hospital only) ANTIBACTERIALS › CEPHALOSPORINS, OTHER eiiii F 550

PDF page 581

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises ceftolozane with tazobactam may inﬂuence driving and performance of skilled tasks—increased risk of dizziness.

PDF page 581

Dose text by age group

Adult

1/0.5 g every 8 hours for 4–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

1/0.5 g every 8 hours for 7 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/1 g every 8 hours for 8–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Ceftolozane with tazobactam

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 580, 581

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 580

National Funding Access Decisions

PDF page 581

Safety

Interactions

→Appendix 1: cephalosporins

PDF page 580

Side Effects

PDF page 580

Pregnancy

Manufacturer advises to use only if potential beneﬁt outweighs risk—toxicity in animal studies with tazobactam.

PDF page 580

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 580

Renal Impairment

PDF page 580

Dose and formulations

Directions For Administration

PDF pages 580, 581

Medicinal Forms

PDF page 581

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises ceftolozane with tazobactam may inﬂuence driving and performance of skilled tasks—increased risk of dizziness.

PDF page 581

Dose text by age group

Adult

1/0.5 g every 8 hours for 4–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

1/0.5 g every 8 hours for 7 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Adult

2/1 g every 8 hours for 8–14 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 580

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.